Home › Funds › Mass General Brigham, Inc › MAZE
Mass General Brigham, Inc position in MAZE
MAZE THERAPEUTICS INC · Health Care
Mass General Brigham, Inc reported holding 249,636 shares of MAZE (MAZE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 1.57% of its reported portfolio and ranking #5 among its reported holdings. Mass General Brigham, Inc has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-03 · Source: SEC EDGAR Form 13F-HR
How Mass General Brigham, Inc's MAZE position evolved
Mass General Brigham, Inc first disclosed a stake in MAZE in Q4 2025 at 239,994 shares (US$9.9M). Across 4 filings, Mass General Brigham, Inc increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 249,636 shares valued at US$6.8M — an increase of 9,642 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 239.99K | $9.94M | New |
| Q1 2026 | 239.99K | $7.16M | Hold |
| Q2 2026 | 239.99K | $7.16M | Hold |
| Q3 2026 | 249.64K | $6.79M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MAZE and 13F data
MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MAZE
- Frazier Life Sciences Management, L.P. 5.03M sh · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M sh · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M sh · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M sh · $111.38M · Q2 2026
- Logos Global Management LP 1.94M sh · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M sh · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M sh · $47.80M · Q2 2026
- Alphabet Inc. 1.39M sh · $41.44M · Q2 2026
- BRAIDWELL LP 1.14M sh · $34.02M · Q2 2026
- Farallon Capital Management 1.11M sh · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M sh · $33.06M · Q2 2026
- General Catalyst Group Management, LLC 1.04M sh · $30.91M · Q2 2026
More on Mass General Brigham, Inc
FAQ
How long has Mass General Brigham, Inc held MAZE?
Mass General Brigham, Inc has disclosed MAZE holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Mass General Brigham, Inc's current position in MAZE?
As of Q3 2026, Mass General Brigham, Inc holds 249.64K shares of MAZE (MAZE THERAPEUTICS INC), valued at $6.79M, representing 1.57% of its reported portfolio and ranking #5.
Has Mass General Brigham, Inc been buying or selling MAZE?
In the latest 13F filing (Q3 2026), Mass General Brigham, Inc increased its position in MAZE.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.